Feng Chi Biotech Corp. (TPEX:6744)

Market Cap	244.86M -24.3%
Revenue (ttm)	177.36M +3.7%
Net Income	14.47M -12.8%
EPS	0.94 -12.2%
Shares Out	15.40M
PE Ratio	16.92
Forward PE	n/a
Dividend	0.95 (6.13%)
Ex-Dividend Date	Jul 21, 2026

Volume	1,004
Open	15.90
Previous Close	15.50
Day's Range	15.90 - 15.90
52-Week Range	13.30 - 22.10
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Feng Chi Biotech

Feng Chi Biotech Corp. engages in the wholesale and retail of medical devices and precision instruments and biotechnology services in Taiwan and internationally. The company provides preimplantation genetic testing, prenatal testing, precision medicine, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services, as well as infectious disease detection services. It also distributes various genetic and medical testing services. The company was founded in 1992 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 32
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6744

Financial Performance

In 2025, Feng Chi Biotech's revenue was 177.36 million, an increase of 3.66% compared to the previous year's 171.10 million. Earnings were 14.47 million, a decrease of -12.78%.